Amgen Inc
NASDAQ:AMGN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
258.59
345.46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
AMGN
stock under the Base Case scenario is
303.51
USD.
Compared to the current market price of 340.16 USD,
Amgen Inc
is
Overvalued by 11%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Amgen Inc.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
S
|
Seagen Inc
F:SGT
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
A potential wave of biosimilar competition for flagship products such as Enbrel and Otezla threatens to erode market share and pressure margins as payers increasingly turn to lower-cost alternatives.
Amgen’s development pipeline faces uncertainties, with notable delays or setbacks in key therapeutic areas like oncology and cardiovascular, raising concerns about insufficient near-term replacement for maturing products.
Rising scrutiny of high drug prices in the U.S. and abroad could constrain Amgen’s ability to maintain premium pricing for its biologics, potentially dampening revenue and profit growth.
Amgen’s recent acquisitions, including its purchase of ChemoCentryx, expand its footprint in high-value rare disease and autoimmune segments, potentially offsetting sales declines from mature blockbuster drugs.
Strong commercial execution and a diversified portfolio of biologics, including Prolia and Repatha, position Amgen to leverage its robust global distribution infrastructure and maintain stable revenue streams.
Significant free cash flow generation and disciplined capital allocation enable continued investment in innovative drug candidates and support shareholder returns through dividends and buybacks, strengthening investor confidence.
Revenue & Expenses Breakdown
Amgen Inc
Balance Sheet Decomposition
Amgen Inc
| Current Assets | 27.9B |
| Cash & Short-Term Investments | 9.4B |
| Receivables | 8.5B |
| Other Current Assets | 10B |
| Non-Current Assets | 62.3B |
| PP&E | 7.2B |
| Intangibles | 41.8B |
| Other Non-Current Assets | 13.2B |
| Current Liabilities | 21.8B |
| Accounts Payable | 19.6B |
| Other Current Liabilities | 2.2B |
| Non-Current Liabilities | 58.7B |
| Long-Term Debt | 52.4B |
| Other Non-Current Liabilities | 6.3B |
Free Cash Flow Analysis
Amgen Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Amgen Inc
|
Revenue
|
36B
USD
|
|
Cost of Revenue
|
-10.1B
USD
|
|
Gross Profit
|
25.9B
USD
|
|
Operating Expenses
|
-13.8B
USD
|
|
Operating Income
|
12.1B
USD
|
|
Other Expenses
|
-5.1B
USD
|
|
Net Income
|
7B
USD
|
AMGN Profitability Score
Profitability Due Diligence
Amgen Inc's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Amgen Inc's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
AMGN Solvency Score
Solvency Due Diligence
Amgen Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Score
Amgen Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMGN Price Targets Summary
Amgen Inc
According to Wall Street analysts, the average 1-year price target for
AMGN
is 327.38 USD
with a low forecast of 181.8 USD and a high forecast of 420 USD.
Dividends
Current shareholder yield for
AMGN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
AMGN
stock under the Base Case scenario is
303.51
USD.
Compared to the current market price of 340.16 USD,
Amgen Inc
is
Overvalued by 11%.